CoChat

4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023

Open access
ElSayed, Nuha A., Aleppo, Grazia, Aroda, Vanita R., Bannuru, Raveendhara R., Brown, Florence M., Bruemmer, Dennis, Collins, Billy S., Cusi, Kenneth, Hilliard, Marisa E., Isaacs, Diana, Johnson, Eric L., Kahan, Scott, Khunti, Kamlesh, Leon, Jose, Lyons, Sarah K., Perry, Mary Lou, Prahalad, Priya, Pratley, Richard E., Seley, Jane Jeffrie, Stanton, Robert C., Younossi, Zobair, Gabbay, Robert A., American Diabetes Association · 2023 · Diabetes Care
Cited by 222

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc23-s004

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Research works printed but not linked: 163

  1. Stellefson, 2013, The chronic care model and diabetes management in US primary care settings: a systematic review, Prev Chronic Dis, 10, E26, 10.5888/pcd10.120180 · DOI · Paper page
  2. Gabbay, 2011, Multipayer patient-centered medical home implementation guided by the chronic care model, Jt Comm J Qual Patient Saf, 37, 265
  3. UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  4. Diabetes Control and Complications Trial Research Group; NathanDM, GenuthS, LachinJ, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977–986 · DOI · Paper page
  5. White, 2001, Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT), J Pediatr, 139, 804, 10.1067/mpd.2001.118887 · DOI · Paper page
  6. Rodriguez, 2022, Improving quality outcomes: the value of diabetes care and education specialists, Clin Diabetes, 40, 356, 10.2337/cd21-0089 · DOI
  7. Anderson, 2000, Compliance and adherence are dysfunctional concepts in diabetes care, Diabetes Educ, 26, 597, 10.1177/014572170002600405 · DOI · Paper page
  8. Sarkar, 2006, Is self-efficacy associated with diabetes self-management across race/ethnicity and health literacy?, Diabetes Care, 29, 823, 10.2337/diacare.29.04.06.dc05-1615 · DOI · Paper page
  9. Robinson, 2020, Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2020, MMWR Morb Mortal Wkly Rep, 69, 130, 10.15585/mmwr.mm6905a3 · DOI
  10. Freedman, 2020, Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older—United States, 2020, MMWR Morb Mortal Wkly Rep, 69, 133, 10.15585/mmwr.mm6905a4 · DOI
  11. Lee, 2018, Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep, 67, 1271, 10.15585/mmwr.mm6745a4 · DOI
  12. Goeijenbier, 2017, Benefits of flu vaccination for persons with diabetes mellitus: a review, Vaccine, 35, 5095, 10.1016/j.vaccine.2017.07.095 · DOI
  13. Yedlapati, 2021, Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis, J Am Heart Assoc, 10, e019636, 10.1161/JAHA.120.019636 · DOI · Paper page
  14. Smith, 2000, Use of influenza and pneumococcal vaccines in people with diabetes, Diabetes Care, 23, 95, 10.2337/diacare.23.1.95 · DOI · Paper page
  15. Ahmed, 2020, Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-United States, Clin Infect Dis, 70, 2484, 10.1093/cid/ciz739 · DOI · Paper page
  16. Grant, 2011, Defining patient complexity from the primary care physician’s perspective: a cohort study, Ann Intern Med, 155, 797, 10.7326/0003-4819-155-12-201112200-00001 · DOI · Paper page
  17. Tinetti, 2012, Designing health care for the most common chronic condition—multimorbidity, JAMA, 307, 2493, 10.1001/jama.2012.5265 · DOI · Paper page
  18. Sudore, 2012, Symptom burden of adults with type 2 diabetes across the disease course: diabetes & aging study, J Gen Intern Med, 27, 1674, 10.1007/s11606-012-2132-3 · DOI · Paper page
  19. Borgnakke, 2013, Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence, J Periodontol, 84, S135, 10.1902/jop.2013.1340013 · DOI · Paper page
  20. De Block, 1999, High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry, J Clin Endocrinol Metab, 84, 4062
  21. Triolo, 2011, Additional autoimmune disease found in 33% of patients at type 1 diabetes onset, Diabetes Care, 34, 1211, 10.2337/dc10-1756 · DOI · Paper page
  22. Kahaly, 2016, Type 1 diabetes associated autoimmunity, Autoimmun Rev, 15, 644, 10.1016/j.autrev.2016.02.017 · DOI · Paper page
  23. Eisenbarth, 2004, Autoimmune polyendocrine syndromes, N Engl J Med, 350, 2068, 10.1056/NEJMra030158 · DOI · Paper page
  24. Rubio-Tapia, 2013, ACG clinical guidelines: diagnosis and management of celiac disease, Am J Gastroenterol, 108, 656, 10.1038/ajg.2013.79 · DOI · Paper page
  25. Suh, 2011, Diabetes and cancer: is diabetes causally related to cancer?, Diabetes Metab J, 35, 193, 10.4093/dmj.2011.35.3.193 · DOI
  26. Giovannucci, 2010, Diabetes and cancer: a consensus report, CA Cancer J Clin, 60, 207, 10.3322/caac.20078 · DOI · Paper page
  27. Ohara, 2011, Glucose tolerance status and risk of dementia in the community: the Hisayama study, Neurology, 77, 1126, 10.1212/WNL.0b013e31822f0435 · DOI · Paper page
  28. Cukierman-Yaffe, 2009, Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial, Diabetes Care, 32, 221, 10.2337/dc08-1153 · DOI · Paper page
  29. Lacy, 2020, Severe hypoglycemia and cognitive function in older adults with type 1 diabetes: the Study of Longevity in Diabetes (SOLID), Diabetes Care, 43, 541, 10.2337/dc19-0906 · DOI
  30. Ooi, 2011, Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairment, Cochrane Database Syst Rev, 4, CD007220
  31. Lecube, 2006, Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study, Diabetes Care, 29, 1096, 10.2337/dc05-2509 · DOI · Paper page
  32. Hum, 2017, Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus, Diabetes Care, 40, 1173, 10.2337/dc17-0485 · DOI · Paper page
  33. Carnovale, 2019, The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis, Acta Diabetol, 56, 341, 10.1007/s00592-018-1257-1 · DOI
  34. Piciucchi, 2015, Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment, Int J Endocrinol, 2015, 595649, 10.1155/2015/595649 · DOI
  35. Lee, 2016, Bidirectional relationship between diabetes and acute pancreatitis: a population-based cohort study in Taiwan, Medicine (Baltimore), 95, e2448, 10.1097/MD.0000000000002448 · DOI
  36. Das, 2014, Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis, Gut, 63, 818, 10.1136/gutjnl-2013-305062 · DOI · Paper page
  37. Petrov, 2017, Diabetes of the exocrine pancreas: American Diabetes Association-compliant lexicon, Pancreatology, 17, 523, 10.1016/j.pan.2017.06.007 · DOI
  38. Tkac, 2017, Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes, Diabetes Care, 40, 284, 10.2337/dc15-1707 · DOI
  39. Bellin, 2015, Total pancreatectomy with islet autotransplantation: summary of an NIDDK workshop, Ann Surg, 261, 21, 10.1097/SLA.0000000000001059 · DOI
  40. Sutherland, 2012, Total pancreatectomy and islet autotransplantation for chronic pancreatitis, J Am Coll Surg, 214, 409, 10.1016/j.jamcollsurg.2011.12.040 · DOI · Paper page
  41. Webb, 2008, Islet auto transplantation following total pancreatectomy: a long-term assessment of graft function, Pancreas, 37, 282, 10.1097/mpa.0b013e31816fd7b6 · DOI
  42. Wu, 2015, Systematic review and meta-analysis of islet autotransplantation after total pancreatectomy in chronic pancreatitis patients, Endocr J, 62, 227, 10.1507/endocrj.EJ14-0510 · DOI
  43. Janghorbani, 2007, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture, Am J Epidemiol, 166, 495, 10.1093/aje/kwm106 · DOI · Paper page
  44. Vestergaard, 2007, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis, Osteoporos Int, 18, 427, 10.1007/s00198-006-0253-4 · DOI · Paper page
  45. Schwartz, 2011, Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes, JAMA, 305, 2184, 10.1001/jama.2011.715 · DOI · Paper page
  46. Taylor, 2015, Possible adverse effects of SGLT2 inhibitors on bone, Lancet Diabetes Endocrinol, 3, 8, 10.1016/S2213-8587(14)70227-X · DOI · Paper page
  47. Baiduc, 2019, Epidemiology of diabetes and hearing loss, Semin Hear, 40, 281, 10.1055/s-0039-1697643 · DOI
  48. Helzner, 2016, Type 2 diabetes and hearing impairment, Curr Diab Rep, 16, 3, 10.1007/s11892-015-0696-0 · DOI
  49. Bainbridge, 2008, Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004, Ann Intern Med, 149, 1, 10.7326/0003-4819-149-1-200807010-00231 · DOI · Paper page
  50. Schade, 2018, Hearing impairment and type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort, Diabetes Care, 41, 2495, 10.2337/dc18-0625 · DOI
  51. Rasmussen, 2018, Prevalence of taste and smell impairment in adults with diabetes: a cross-sectional analysis of data from the National Health and Nutrition Examination Survey (NHANES), Prim Care Diabetes, 12, 453, 10.1016/j.pcd.2018.05.006 · DOI
  52. Li, 2010, Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005–2006, Prev, 51, 18
  53. West, 2006, Prevalence of obstructive sleep apnoea in men with type 2 diabetes, Thorax, 61, 945, 10.1136/thx.2005.057745 · DOI · Paper page
  54. Bibbins-Domingo, 2017, Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement, JAMA, 317, 407, 10.1001/jama.2016.20325 · DOI · Paper page
  55. Shaw, 2008, Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention, Diabetes Res Clin Pract, 81, 2, 10.1016/j.diabres.2008.04.025 · DOI · Paper page
  56. Khader, 2006, Periodontal status of diabetics compared with nondiabetics: a meta-analysis, J Diabetes Complications, 20, 59, 10.1016/j.jdiacomp.2005.05.006 · DOI · Paper page
  57. Casanova, 2014, Diabetes and periodontal disease: a two-way relationship, Br Dent J, 217, 433, 10.1038/sj.bdj.2014.907 · DOI · Paper page
  58. Simpson, 2015, Treatment of periodontal disease for glycaemic control in people with diabetes mellitus, Cochrane Database Syst Rev, CD004714
  59. Lomonaco, 2021, Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening, Diabetes Care, 44, 399, 10.2337/dc20-1997 · DOI · Paper page
  60. Ciardullo, 2021, High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes, Diabetes Care, 44, 519, 10.2337/dc20-1778 · DOI · Paper page
  61. Barb, 2021, Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease, Obesity (Silver Spring), 29, 1950, 10.1002/oby.23263 · DOI
  62. Stefan, 2022, A global view of the interplay between non-alcoholic fatty liver disease and diabetes, Lancet Diabetes Endocrinol, 10, 284, 10.1016/S2213-8587(22)00003-1 · DOI · Paper page
  63. Paik, 2020, Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD, Hepatology, 72, 1605, 10.1002/hep.31173 · DOI · Paper page
  64. Simon, 2021, Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort, Gut, 70, 1375, 10.1136/gutjnl-2020-322786 · DOI · Paper page
  65. Burra, 2020, NAFLD and liver transplantation: disease burden, current management and future challenges, JHEP Rep, 2, 100192, 10.1016/j.jhepr.2020.100192 · DOI · Paper page
  66. Younossi, 2022, A global survey of physicians knowledge about nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 20, e1456, 10.1016/j.cgh.2021.06.048 · DOI · Paper page
  67. Kanwal, 2021, Preparing for the NASH epidemic: a call to action, Diabetes Care, 44, 2162, 10.2337/dci21-0020 · DOI · Paper page
  68. Kanwal, 2021, Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease, Gastroenterology, 161, 1657, 10.1053/j.gastro.2021.07.049 · DOI · Paper page
  69. Gellert-Kristensen, 2020, Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population, Hepatology, 72, 845, 10.1002/hep.31238 · DOI · Paper page
  70. Stender, 2017, Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci, Nat Genet, 49, 842, 10.1038/ng.3855 · DOI · Paper page
  71. Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
  72. Mantovani, 2018, Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis, Diabetes Care, 41, 372, 10.2337/dc17-1902 · DOI · Paper page
  73. Duell, 2022, Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association, Arterioscler Thromb Vasc Biol, 42, e168, 10.1161/ATV.0000000000000153 · DOI · Paper page
  74. Ciardullo, 2022, Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: a systematic review and meta-analysis, Biomolecules, 12, 105, 10.3390/biom12010105 · DOI
  75. Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, e1001680, 10.1371/journal.pmed.1001680 · DOI · Paper page
  76. Song, 2021, Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: a meta-analysis of observational studies, J Diabetes Investig, 12, 1471, 10.1111/jdi.13489 · DOI
  77. de Vries, 2020, Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis, J Clin Endocrinol Metab, 105, dgaa575, 10.1210/clinem/dgaa575 · DOI
  78. Cusi, 2017, Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes, Diabetes Obes Metab, 19, 1630, 10.1111/dom.12973 · DOI · Paper page
  79. Arab, 2020, Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease, Ann Hepatol, 19, 674, 10.1016/j.aohep.2020.09.006 · DOI
  80. Eslam, 2020, The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, Hepatol Int, 14, 889, 10.1007/s12072-020-10094-2 · DOI · Paper page
  81. Maximos M , BrilF, Portillo Sanchez, The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology2014;61:153–160 · DOI · Paper page
  82. Unalp-Arida, 2017, Liver fibrosis scores predict liver disease mortality in the United States population, Hepatology, 66, 84, 10.1002/hep.29113 · DOI · Paper page
  83. Lee, 2021, Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review, Liver Int, 41, 261, 10.1111/liv.14669 · DOI · Paper page
  84. Qadri, 2022, Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease, J Clin Endocrinol Metab, 107, e2008, 10.1210/clinem/dgab933 · DOI
  85. Bril, 2020, Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes, Diabetes Care, 43, 290, 10.2337/dc19-1071 · DOI · Paper page
  86. Anstee, 2019, Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials, Hepatology, 70, 1521, 10.1002/hep.30842 · DOI · Paper page
  87. Singh, 2020, Accuracy of noninvasive fibrosis scores to detect advanced fibrosis in patients with type-2 diabetes with biopsy-proven nonalcoholic fatty liver disease, J Clin Gastroenterol, 54, 891, 10.1097/MCG.0000000000001339 · DOI
  88. Ishiba, 2018, The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study, J Gastroenterol, 53, 1216, 10.1007/s00535-018-1474-y · DOI
  89. Castera, 2019, Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1264, 10.1053/j.gastro.2018.12.036 · DOI · Paper page
  90. Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042 · DOI · Paper page
  91. Mózes, 2022, Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis, Gut, 71, 1006, 10.1136/gutjnl-2021-324243 · DOI · Paper page
  92. Elhence, 2022, Compensated advanced chronic liver disease in nonalcoholic fatty liver disease: two-step strategy is better than Baveno criteria, Dig Dis Sci
  93. Chan, 2019, Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis, Clin Gastroenterol Hepatol, 17, 2570, 10.1016/j.cgh.2019.03.006 · DOI
  94. Petta, 2019, Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 114, 916, 10.14309/ajg.0000000000000153 · DOI · Paper page
  95. Lazarus, 2021, Defining comprehensive models of care for NAFLD, Nat Rev Gastroenterol Hepatol, 18, 717, 10.1038/s41575-021-00477-7 · DOI
  96. Wong, 2022, Management of NAFLD in primary care settings, Liver Int, 42, 2377, 10.1111/liv.15404 · DOI · Paper page
  97. Long, 2022, AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review, Gastroenterology, 163, 764, 10.1053/j.gastro.2022.06.023 · DOI · Paper page
  98. Cusi, 2017, Nonalcoholic steatohepatitis in nonobese patients: not so different after all, Hepatology, 65, 4, 10.1002/hep.28839 · DOI
  99. Cusi, 2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, 711, 10.1053/j.gastro.2012.02.003 · DOI · Paper page
  100. Akbulut, 2022, The effect of a Mediterranean diet vs. a low-fat diet on non-alcoholic fatty liver disease in children: a randomized trial, Int J Food Sci Nutr, 73, 357, 10.1080/09637486.2021.1979478 · DOI
  101. Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 · DOI · Paper page
  102. Gepner, 2019, The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content, J Hepatol, 71, 379, 10.1016/j.jhep.2019.04.013 · DOI · Paper page
  103. Younossi, 2021, AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review, Gastroenterology, 160, 912, 10.1053/j.gastro.2020.11.051 · DOI · Paper page
  104. Plauth, 2019, ESPEN guideline on clinical nutrition in liver disease, Clin Nutr, 38, 485, 10.1016/j.clnu.2018.12.022 · DOI · Paper page
  105. Orci, 2016, Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression, Clin Gastroenterol Hepatol, 14, 1398, 10.1016/j.cgh.2016.04.036 · DOI · Paper page
  106. Younossi, 2018, The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options, J Hepatol, 69, 1365, 10.1016/j.jhep.2018.08.013 · DOI · Paper page
  107. Patel Chavez, 2022, The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD, J Clin Endocrinol Metab, 107, 29, 10.1210/clinem/dgab578 · DOI · Paper page
  108. Budd, 2020, Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease, Curr Diab Rep, 20, 59, 10.1007/s11892-020-01349-1 · DOI
  109. Huang, 2021, First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients, Hepatol Int, 15, 1136, 10.1007/s12072-021-10242-2 · doi:10.1007/s12072-021-10242-2
  110. Noureddin, 2020, Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis, Gastroenterology, 159, 1985, 10.1053/j.gastro.2020.07.050 · DOI · Paper page
  111. Mahady, 2012, Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis, Hepatology, 56, 2172, 10.1002/hep.25887 · DOI
  112. Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X · DOI · Paper page
  113. Gastaldelli, 2022, Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial, Lancet Diabetes Endocrinol, 10, 393, 10.1016/S2213-8587(22)00070-5 · DOI · Paper page
  114. Castera, 2023, Diabetes and cirrhosis: current concepts on diagnosis and management, Hepatology, 77, 2128, 10.1097/HEP.0000000000000263 · DOI
  115. Loomba, 2023, Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial, Lancet Gastroenterol Hepatol, 8, 511, 10.1016/S2468-1253(23)00068-7 · DOI · Paper page
  116. Ramai, 2021, Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma, Aliment Pharmacol Ther, 53, 977, 10.1111/apt.16335 · DOI
  117. Kim, 2017, Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 15, 1521, 10.1016/j.cgh.2017.04.039 · DOI · Paper page
  118. Kaplan, 2019, Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis, Gastroenterology, 156, 1693, 10.1053/j.gastro.2019.01.026 · DOI · Paper page
  119. Roberts, 2020, COVID-19: a complex multisystem disorder, Br J Anaesth, 125, 238, 10.1016/j.bja.2020.06.013 · DOI
  120. Chudasama, 2021, Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K, BMC Infect Dis, 21, 908, 10.1186/s12879-021-06600-y · DOI
  121. Holman, 2020, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol, 8, 823, 10.1016/S2213-8587(20)30271-0 · DOI · Paper page
  122. Martin, 2020, Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: results from an observational cohort study, EClinicalMedicine, 25, 100466, 10.1016/j.eclinm.2020.100466 · DOI
  123. Singh, 2020, Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis, Diabetes Obes Metab, 22, 1915, 10.1111/dom.14124 · DOI · Paper page
  124. Hartmann-Boyce, 2020, Diabetes and COVID-19: risks, management, and learnings from other national disasters, Diabetes Care, 43, 1695, 10.2337/dc20-1192 · DOI · Paper page
  125. Hartmann-Boyce, 2021, Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews, Diabetes Care, 44, 2790, 10.2337/dc21-0930 · DOI
  126. Barron, 2020, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, 8, 813, 10.1016/S2213-8587(20)30272-2 · DOI · Paper page
  127. Khunti, 2023, The impact of the COVID-19 pandemic on ethnic minority groups with diabetes, Diabetes Care, 46, 228, 10.2337/dc21-2495 · DOI
  128. Chen, 2022, Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review, J Infect Dis, 226, 1593, 10.1093/infdis/jiac136 · DOI · Paper page
  129. Khunti, 2021, COVID-19, hyperglycemia, and new-onset diabetes, Diabetes Care, 44, 2645, 10.2337/dc21-1318 · DOI · Paper page
  130. Qeadan, 2022, The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: a nationwide cohort from the US using the Cerner Real-World Data, PLoS One, 17, e0266809, 10.1371/journal.pone.0266809 · DOI
  131. Shulman, 2022, Examination of trends in diabetes incidence among children during the COVID-19 pandemic in Ontario, Canada, from March 2020 to September 2021, JAMA Netw Open, 5, e2223394, 10.1001/jamanetworkopen.2022.23394 · DOI
  132. Kamrath, 2020, Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany, JAMA, 324, 801, 10.1001/jama.2020.13445 · DOI · Paper page
  133. Misra, 2021, Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study, Lancet Diabetes Endocrinol, 9, 671, 10.1016/S2213-8587(21)00208-4 · DOI
  134. Violant-Holz, 2020, Psychological health and physical activity levels during the COVID-19 pandemic: a systematic review, Int J Environ Res Public Health, 17, E9419, 10.3390/ijerph17249419 · DOI · Paper page
  135. Alessi, 2022, One in ten patients with diabetes have suicidal thoughts after 1 year of the COVID-19 pandemic: we need to talk about diabetes and mental health not only during Suicide Prevention Awareness Month, Acta Diabetol, 59, 143, 10.1007/s00592-021-01807-6 · doi:10.1007/s00592-021-01807-6
  136. Chao, 2022, Changes in the prevalence of symptoms of depression, loneliness, and insomnia in U.S. older adults with type 2 diabetes during the COVID-19 pandemic: the Look AHEAD Study, Diabetes Care, 45, 74, 10.2337/dc21-1179 · DOI
  137. Stockwell, 2021, Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review, BMJ Open Sport Exerc Med, 7, e000960, 10.1136/bmjsem-2020-000960 · DOI · Paper page
  138. O’Donnell MB , HilliardME, CaoVT, “It just kind of feels like a different world now:” stress and resilience for adolescents with type 1 diabetes in the era of COVID-19. Front Clin Diabetes Healthcare. Accessed 7 October 2022. Available from https://www.frontiersin.org/articles/10.3389/fcdhc.2022.835739 · DOI
  139. Wang, 2021, Predictors of mood, diabetes-specific and COVID-19-specific experiences among parents of early school-age children with type 1 diabetes during initial months of the COVID-19 pandemic, Pediatr Diabetes, 22, 1071, 10.1111/pedi.13255 · DOI
  140. Ferguson, Impacts of the COVID-19 pandemic on pediatric type 1 diabetes management: a qualitative study, Sci Diabetes Self Manag Care.
  141. Mohseni, 2021, Challenges of routine diabetes care during COVID-19 era: a systematic search and narrative review, Prim Care Diabetes, 15, 918, 10.1016/j.pcd.2021.07.017 · DOI
  142. Ratzki-Leewing, 2021, COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study), BMJ Open, 11, e049782, 10.1136/bmjopen-2021-049782 · DOI
  143. Seidu, 2022, The impact of the COVID pandemic on primary care diabetes services in the UK: a cross-sectional national survey of views of health professionals delivering diabetes care, Prim Care Diabetes, 16, 257, 10.1016/j.pcd.2021.12.015 · DOI
  144. Carr, 2022, Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care, BMJ Qual Saf, 31, 503, 10.1136/bmjqs-2021-013613 · DOI · Paper page
  145. Vamos, 2022, Indirect effects of the COVID-19 pandemic on people with type 2 diabetes: time to urgently move into a recovery phase, BMJ Qual Saf, 31, 483, 10.1136/bmjqs-2021-014079 · DOI
  146. Valabhji, 2022, Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study, Lancet Diabetes Endocrinol, 10, 561, 10.1016/S2213-8587(22)00131-0 · doi:10.1016/s2213-8587(22)00131-0
  147. DiabetesontheNet . How to undertake a remote diabetes review. Accessed 29 August 2022. Available from https://diabetesonthenet.com/diabetes-primary-care/how-undertake-remote-diabetes-review/
  148. Nagi, 2021, ABCD position statement on risk stratification of adult patients with diabetes during COVID-19 pandemic, British Journal of Diabetes., 21, 123, 10.15277/bjd.2021.282 · DOI
  149. Alessi, 2021, Telehealth strategy to mitigate the negative psychological impact of the COVID-19 pandemic on type 2 diabetes: a randomized controlled trial, Acta Diabetol, 58, 899, 10.1007/s00592-021-01690-1 · DOI
  150. Kilvert, 2020, Virtual consultations: are we missing anything?, Pract Diabetes, 37, 143, 10.1002/pdi.2288 · DOI
  151. Khunti, 2021, Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England, Lancet Diabetes Endocrinol, 9, 293, 10.1016/S2213-8587(21)00050-4 · DOI · Paper page
  152. Kosiborod, 2021, Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Diabetes Endocrinol, 9, 586, 10.1016/S2213-8587(21)00180-7 · DOI · Paper page
  153. Czeisler, 2021, Health care access and use among adults with diabetes during the COVID-19 pandemic - United States, February-March 2021, MMWR Morb Mortal Wkly Rep, 70, 1597, 10.15585/mmwr.mm7046a2 · DOI
  154. Lipska, 2014, National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011, JAMA Intern Med, 174, 1116, 10.1001/jamainternmed.2014.1824 · DOI · Paper page
  155. Shorr, 1997, Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas, Arch Intern Med, 157, 1681, 10.1001/archinte.1997.00440360095010 · DOI · Paper page
  156. Abdelhafiz, 2015, Hypoglycemia in older people–a less well recognized risk factor for frailty, Aging Dis, 6, 156, 10.14336/AD.2014.0330 · DOI · Paper page
  157. Yun, 2013, Presence of macroalbuminuria predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study, Diabetes Care, 36, 1283, 10.2337/dc12-1408 · DOI
  158. Chelliah, 2004, Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention, Drugs Aging, 21, 511, 10.2165/00002512-200421080-00003 · DOI · Paper page
  159. Centers for Disease Control and Prevention (CDC), 2011, Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 60, 1709
  160. Demicheli, 2018, Vaccines for preventing influenza in the elderly, Cochrane Database Syst Rev, 2, CD004876
  161. Centers for Disease Control and Prevention (CDC), 2010, Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23), MMWR Morb Mortal Wkly Rep, 59, 1102
  162. Falkenhorst, 2017, Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis, PLoS One, 12, e0169368, 10.1371/journal.pone.0169368 · DOI · Paper page
  163. Dooling, 2018, Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines, MMWR Morb Mortal Wkly Rep, 67, 103, 10.15585/mmwr.mm6703a5 · DOI · Paper page

Cited by

Metadata

Authors
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., Younossi, Z., Gabbay, R. A., & American Diabetes Association
Venue
Diabetes Care
Published
2022-12-12
Volume
46
Issue
Supplement_1
Pages
s49-s67.2
ISSN
0149-5992 (ISSN-L)
OpenAlex
W4311264007
Cited by
222
References
82
FWCI
30.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.